Rapid Dose Therapeutics (CSE:DOSE) is a biotechnology company revolutionizing drug delivery through innovation, specifically with their flagship product QuickStrip. It is a thin oral dissolvable film that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines & cannabis), which are delivered quickly into the bloodstream for rapid onset and effect in seconds. The company today announced the inauguration and appointment of the first three industry-leading appointees of its advisory board.
Ron Brooks
Ron Brooks, CPA CA ICD.D is a seasoned finance and corporate executive with significant experience in risk management and assisting companies during the high growth phase where he can help instill processes, procedures, controls to manage this rapid pace of expansion. He’s served on boards for TSX-listed as well as NASDAQ listed entities at various times serving as chairperson for audit committees or governing board memberships. Ron’s experience in education, finance, and banking gives him an edge as he takes on his new role at this not-for profit organization that provides rehabilitation services for those struggling with substance abuse issues. Ron Brooks is presently deeply involved in a leading not-for-profit entity that provides recovery services for people with substance abuse issues while also being CEO of $1 billion Education Fund during 15 years spent working as senior executive Corporate Finance director major international banks such HSBC Group.
Nick DiRenzo
Nick DiRenzo, FCA, FCPA, ICD.D is a strategic business leader who has over 35 years of experience in successful leadership and management. He’s had success across several sectors, including insurance, wealth management healthcare mortgage credit unions banking real estate in Canada and the United States. Recently retired from Sun Life Financial as President he now shares his expertise with firms around North America to help them achieve their goals through innovation and technology-driven solutions
Anne Lachance
Anne Lachance, ICD.D is one of Canada’s leading corporate and financial communications practitioners who advises companies domestically and internationally on critical business matters like strategy, reputation management or change management. She was co-founder of Kaiser Lachance Communications from 2011 to 2020 where the company ranked in Canadian Business’s Growth 500 list every year since its inception in 2018 until this past 2019 ranking as number two for a total revenue growth rate over 420%. Previously, Anne was Fleishman-Hillard Senior Vice President and Senior Partner where she founded and led the Canadian Financial and Investor Communications along withserving as Co-Chair for the firm’s global practice.
Anne is a skilled professional with an in-depth understanding of the private, public and not-for profit sectors. She has worked for or on behalf of over 100 different organizations ranging from small startups to large publicly listed corporations as well as raising millions dollars for charitable causes through her work at non profits. Anne Lachance understands what it takes to succeed within these various environments whether that be maximizing profitability while still maintaining employee morale, optimizing efficiency to improve company performance or developing strategies without breaking budgets.
Rapid Dose CEO Mark Upsdell Comment
“We have reached a transformational time for the Company as our innovative intellectual property is gaining acceptance as a game changer in the delivery of traditional medications, vaccines, cannabis and nutraceuticals in an orally dissolvable film,” said Mark Upsdell, CEO, Rapid Dose Therapeutics.
“As we set our sights on global expansion and scale through strategic alliances and proprietary commercialization opportunities, our management agreed that the time was ideal to formalize our advisory board with industry leading experts to support our growth. We welcome our new advisors Ron Brooks, Nick DiRenzo and Anne Lachance to the team.”
